The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1058 ET – Eli Lilly is expanding the reach of its GLP-1 drugs internationally, a market with significant potential for the company especially as it launches its GLP-1 pill orforglipron. “Based on results over the past several quarters, international demand for GLP-1s is running ahead of our expectations and LLY remains in a clear position of strength based on Mounjaro’s superior profile and the upcoming launch of orforglipron,” the analysts say. “[International] Mounjaro sales are now annualizing to $12 billion despite what we view as a still highly underpenetrated market.” Meanwhile, orforglipron, with its lower price and better scalability, has a significant opportunity internationally, the analysts say. (nicholas.miller@wsj.com)
Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8